MHRA's devices head to join outgoing CEO in retiring later this year

london uk big ben
Medicines and Healthcare products Regulatory Agency CEO Ian Hudson previously announced plans to step down from the agency this September. (Pixabay)

The medical devices director of the U.K. Medicines and Healthcare products Regulatory Agency has begun a monthslong timeline to retire from the position—the second top MHRA administrator to do so in the wake of Brexit after the CEO announced his own plans to step down last year.

Devices head John Wilkinson will depart at the end of October. He joined the agency in 2012 after serving as chief executive of Eucomed, the European medical technology industry association.

During his time at the MHRA, Wilkinson helped lead the agency’s efforts on the new EU regulations governing medical devices and in vitro diagnostics that took effect in May 2017.

WEBINAR

Webinar: Meet the Challenge of Complex Protein Expression

As market demand continues to rise for more potent and effective therapeutics, biologic pipelines are evolving from standard antibody formats to next-generation biologics (NGBs). In this webinar we will discuss and demonstrate application through case studies, two significant enhancements to Lonza’s GS Xceed® expression system to help address the challenges of NGBs.

He also chaired the Competent Authorities Medical Devices Executive, which guides regulatory collaborations between EU member states and the European Commission, and had previously been named an officer of the Order of the British Empire for his contributions to the medical device industry.

“These decisions are never easy to make, and with a very heavy heart, I have now decided to step down from my role at the Agency,” Wilkinson said in an agency statement. “I felt that now was the right time for me to move on to the next stage of my life.”

RELATED: As Brexit delayed, wannabe next PM wants to slash trial regulations

“These last seven years have been a wonderful experience for myself and I am proud to have been associated with, and worked for, the regulator,” he said. “I would like to express my deepest gratitude to my Agency colleagues with whom I’ve worked—I leave knowing that their drive and commitment in protecting public health will continue unabated.

“It’s for others to judge for themselves the work I’ve done, but my aim has always been to ensure high levels of patient safety whilst creating the right environment for medical devices to develop at a pace which continues to improve people’s lives and contributes to a sustainable development of our health services,” Wilkinson said.

RELATED: Biopharma braces for Brexit impact amid political upheaval

Meanwhile, the CEO of the MHRA, Ian Hudson, is set to make his own exit from the agency the month before; he announced a 10-month departure plan last November.

“I had always intended to reduce my total work commitment to enable me to pursue other things and perhaps have more of a portfolio career by the time I reached 60, which has now happened,” Hudson said at the time. “I feel the time is right for a new person to guide the agency and our work through its next phase, following the U.K.’s departure from the European Union next year.”

RELATED: EMA opens Amsterdam office as Brexit enters critical phase

While the full implications of Brexit remain uncertain amid delays past its March deadline, it is still possible that both Hudson and Wilkinson will leave behind a regulator forced to operate independently from the European Medicines Agency.

The new leadership will have to cope with the effects of Brexit on medical product supply, approvals, importation and other activities, including the move of the EMA’s headquarters from down the street in London’s Canary Wharf over to Amsterdam.

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.